Literature DB >> 27523300

Pipeline for contraceptive development.

Diana L Blithe1.   

Abstract

The high rates of unplanned pregnancy reflect an unmet need for effective contraceptive methods for women, especially for individuals with health risks such as obesity, diabetes, hypertension, and other conditions that may contraindicate use of an estrogen-containing product. Improvements in safety, user convenience, acceptability, and availability of products remain important goals of the contraceptive development program. Another important goal is to minimize the impact of the products on the environment. Development of new methods for male contraception has the potential to address many of these issues of safety for women who have contraindications to effective contraceptive methods but want to protect against pregnancy. It would also address a huge unmet need for men who want to control their fertility. Products under development for men would not introduce ecotoxic hormones into the water system. Published by Elsevier Inc.

Entities:  

Keywords:  Contraception; female contraception; green contraception; male contraception; nonhormonal contraceptive development

Mesh:

Substances:

Year:  2016        PMID: 27523300      PMCID: PMC5159203          DOI: 10.1016/j.fertnstert.2016.07.1115

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  81 in total

1.  Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist.

Authors:  Stephanie T Page; John K Amory; Bradley D Anawalt; Michael S Irwig; Andrew T Brockenbrough; Alvin M Matsumoto; William J Bremner
Journal:  J Clin Endocrinol Metab       Date:  2006-08-29       Impact factor: 5.958

2.  Characteristics associated with suppression of spermatogenesis in a male hormonal contraceptive trial using testosterone and Nestorone(®) gels.

Authors:  M Y Roth; N Ilani; C Wang; S T Page; W J Bremner; R S Swerdloff; C Dart; R Sitruk-Ware; N Kumar; D Blithe; J K Amory
Journal:  Andrology       Date:  2013-09-30       Impact factor: 3.842

3.  Comparison of pharmacodynamic properties of various estrogen formulations.

Authors:  C A Mashchak; R A Lobo; R Dozono-Takano; P Eggena; R M Nakamura; P F Brenner; D R Mishell
Journal:  Am J Obstet Gynecol       Date:  1982-11-01       Impact factor: 8.661

4.  Suppression of spermatogenesis by bisdichloroacetyldiamines is mediated by inhibition of testicular retinoic acid biosynthesis.

Authors:  John K Amory; Charles H Muller; Jakob A Shimshoni; Nina Isoherranen; Jisun Paik; Jan S Moreb; David W Amory; Ryan Evanoff; Alex S Goldstein; Michael D Griswold
Journal:  J Androl       Date:  2010-08-12

Review 5.  Mammalian sperm interactions with the female reproductive tract.

Authors:  Susan S Suarez
Journal:  Cell Tissue Res       Date:  2015-07-17       Impact factor: 5.249

Review 6.  The use of newer progestins for contraception.

Authors:  Regine Sitruk-Ware; Anita Nath
Journal:  Contraception       Date:  2010-05-11       Impact factor: 3.375

7.  Ethinyl estradiol and levonorgestrel in a transdermal contraceptive delivery system.

Authors:  Intira Sriprasert; Frank Z Stanczyk; David F Archer
Journal:  Expert Opin Pharmacother       Date:  2015       Impact factor: 3.889

8.  Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women.

Authors:  Vivian Brache; Regine Sitruk-Ware; Alistair Williams; Diana Blithe; Horacio Croxatto; Narender Kumar; Sushma Kumar; Yun-Yen Tsong; Irving Sivin; Anita Nath; Heather Sussman; Leila Cochon; Maria Jose Miranda; Verónica Reyes; Anibal Faundes; Daniel Mishell
Journal:  Contraception       Date:  2011-12-15       Impact factor: 3.375

Review 9.  Testicular and epididymal ADAMs: expression and function during fertilization.

Authors:  Chunghee Cho
Journal:  Nat Rev Urol       Date:  2012-08-28       Impact factor: 14.432

10.  A new combination of testosterone and nestorone transdermal gels for male hormonal contraception.

Authors:  Niloufar Ilani; Mara Y Roth; John K Amory; Ronald S Swerdloff; Clint Dart; Stephanie T Page; William J Bremner; Regine Sitruk-Ware; Narender Kumar; Diana L Blithe; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2012-07-12       Impact factor: 5.958

View more
  5 in total

1.  Preclinical contraceptive development for men and women.

Authors:  Daniel S Johnston; Erwin Goldberg
Journal:  Biol Reprod       Date:  2020-08-04       Impact factor: 4.285

Review 2.  Update on Novel Hormonal and Nonhormonal Male Contraceptive Development.

Authors:  Jill E Long; Min S Lee; Diana L Blithe
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

Review 3.  The Na+ and K+ transport system of sperm (ATP1A4) is essential for male fertility and an attractive target for male contraception†.

Authors:  Shameem Sultana Syeda; Gladis Sánchez; Jeffrey P McDermott; Kwon Ho Hong; Gustavo Blanco; Gunda I Georg
Journal:  Biol Reprod       Date:  2020-08-04       Impact factor: 4.285

4.  Estimating the market size for a dual prevention pill: adding contraception to pre-exposure prophylaxis (PrEP) to increase uptake.

Authors:  Lorna Begg; Rebecca Brodsky; Barbara Friedland; Sanyukta Mathur; Jim Sailer; George Creasy
Journal:  BMJ Sex Reprod Health       Date:  2020-07-31

5.  Contraceptive Technologies: Looking Ahead to New Approaches to Increase Options for Family Planning.

Authors:  Lisa B Haddad; John W Townsend; Regine Sitruk-Ware
Journal:  Clin Obstet Gynecol       Date:  2021-09-01       Impact factor: 1.966

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.